Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 648-655

  Jonker, D J ^a   Karapetis, C S ^b   Harbison, C ^c   O'Callaghan, C J ^d   Tu, D ^d   Simes, R J ^e   Malone, D P ^c   Langer, C ^f   Tebbutt, N ^g   Price, T J ^h   Shapiro, J ⁱ   Siu, L L ^j   Wong, R P W ^k   Bjarnason, G ^j   Moore, M J ^j   Zalcberg, J R ^g   Khambata Ford, S ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b FLINDERS UNIVERSITY   (Australia)

^c BRISTOL MYERS SQUIBB   (United States)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

^f GENENTECH INC   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF ADELAIDE   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

^j UNIVERSITY OF TORONTO   (Canada)

^k ST BONIFACE GENERAL HOSPITAL   (Canada)

more..

Author keywords

amphiregulin; biomarker; cetuximab; colorectal; EGFR; epiregulin; EREG; K ras

Indexed keywords

CETUXIMAB; EPIREGULIN; K RAS PROTEIN; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893721813     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.753     Document Type: Article

References (12)

1. Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ (2009) Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 27: 1822-1828.
2. Baker JB, Dutta D, Watson D, Maddala T, Munneke BM, Shak S, Rowinsky EK, Xu LA, Harbison CT, Clark EA, Mauro DJ, Khambata-Ford S (2011) Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104: 488-495.
3. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820.
4. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, Humblet Y, Pénault-Llorca F, De Hertogh G, Laurent-Puig P, Van Cutsem E, Tejpar S (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27: 5068-5074.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.
6. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
7. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris 3rd HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237.
8. Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, Yamamoto M, Hayashi K (2012) Amphiregulin and epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer 12: 88.
9. Li XD, Miao SY, Wang GL, Yang L, Shu YQ, Yin YM (2010) Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics. Onkologie 33: 353-358.
10. Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ. Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group (2009) Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 101: 1182-1192.
11. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G (2013) Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13: 49.
12. Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T (2013) A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 139: 367-378.